Bayesian Capital Management, LP Summit Therapeutics Inc. Transaction History
Bayesian Capital Management, LP
- $854 Million
- Q2 2024
A detailed history of Bayesian Capital Management, LP transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Bayesian Capital Management, LP holds 16,499 shares of SMMT stock, worth $344,664. This represents 0.01% of its overall portfolio holdings.
Number of Shares
16,499Holding current value
$344,664% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
138Shares Held
64.4MCall Options Held
1.06MPut Options Held
1.02M-
Baker Bros. Advisors LP New York, NY23.2MShares$485 Million2.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.82MShares$184 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$165 Million0.0% of portfolio
-
State Street Corp Boston, MA4.12MShares$86.1 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.96MShares$61.9 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.2B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...